The aggregation of IFN-α2a-NGR in tumor tissue was significantly more elevated than that in IFN-α2a-treated group after intravenous injections for 30 min, suggesting that IFN-α2a-NGR effectively improves the tumor targeting ability of IFN-α2a and raises the drug concentration in tumor tissues, and thereby increasing the anti-tumor effects in vivo. This evidence concerns the gene IFNA2 and neoplasm.